Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab + pemetrexed is a combination therapy consisting of toripalimab, a humanized monoclonal antibody targeting programmed death protein 1 (PD-1), and pemetrexed, an antifolate chemotherapy agent. Toripalimab acts as an immune checkpoint inhibitor by blocking the PD-1 pathway on T-cells, thereby enhancing the immune system’s ability to recognize and destroy cancer cells. Pemetrexed inhibits folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA replication and cell division in rapidly proliferating tumor cells. This combination has been approved for use as first-line treatment for patients with EGFR mutation-negative and ALK mutation-negative unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in China[3][5]. The regimen is also being studied perioperatively for resectable NSCLC[2][4].
- Brand names
- TUOYI
- Other names
- toripalimab plus pemetrexedtoripalimab in combination with pemetrexed
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on toripalimab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + pemetrexed.